Abstract -This article describes the software and underlined decision support models for the immunophenotype diagnostics of leukosis (leukemia) and lymphomas adjusted for the marker or human leukocyte antigen (CD-antigen) coexpressions. Using the model knowledge base, the decision inference algorithm allows computing the degree of manifestation of the disease subtypes for the input immunophenotype features. Software provides the twostage diagnostics of the leukemia subtypes and the lymphoma diagnostics using the set of the developed rules, possibility to observe the diagnostic results and corresponding reference information. The patient data are organized according to the unified registration card, which provides the possibility to work at the different diagnostic levels: diagnostics of the extended groups of leukosis, diagnostics of the leukemia subtypes, diagnostics of the adult and child lymphomas.
I. INTRODUCTION
Acute leukosis and lymphomas are among the most widespread oncological diseases. In the childhood, these types of the oncological disease take the first place with a frequency of 4.3 cases for the population of 100,000 [1] . In Belarus, the survival rate for these diseases comprises more than 80%, which is comparable with the best world practice, but the situation with the adult patients is slightly worse. The general approach to improve the survival rate is the treatment personalization, based on the enhancement of the diagnostic accuracy.
The basic diagnostic method for these types of disease is the identification of the differentiation stage and maturity of the tumor cells using the immune marker analysis, based on the specified combination of the monoclonal antibodies, which recognize the CD-antigens on the cell surface. At present, more than 30 leukemia and lymphoma subtypes are described with no less than 40 markers, which in different combinations (presence/absence) are used for the diagnostics. The standard marker combination is presented only in less than a half number of cases; the rest is characterized by the presence of the coexpressions, nonrelevant to the particular disease and the absence of some core markers. The diagnostic accuracy depends on the knowledge of all the available marker combinations and the possible coexpressions, which require the higher level of training and deep background in the domain. Therefore, to aid in the diagnostic process we have developed the decision support models and the corresponding software for the differential diagnostics of the leukemia and lymphoma subtypes adjusted for the marker coexpressions. Using the automation of the data processing, the proposed software system helps to differentiate the disease subtypes and thereafter to raise the quality and diagnostic timeliness for the adequate treatment. The first attempts in this direction were made for the childhood leukemia on the basis of the standard combinations of marker expressions with a subsequent identification of coexpressions [1] . In the proposed software system, the decision-making is implemented on the basis of the diagnostic rules, extracted from the database and presented as the weighted marker combinations and the specialized decision inference algorithm for the identification of the degree of manifestation for each disease subtype. The treatment personalization is provided by more accurate diagnostic rules, accounting for marker coexpressions. The application of the software system for the personal training will allow raising the educational level of the specialists dealing with differential diagnostics and reducing the training costs.
II. DECISION SUPPORT MODELS FOR THE DIFFERENTIAL
IMMUNOPHENOTYPE DIAGNOSTICS OF LEUKOSIS AND LYMPHOMAS The decision support models [2] consist of the following components ( Fig. 1) :
 Input data module;  Knowledge base module;  Decision-making module;  Output data module. Input data module provides the following functions:  inputting and storing the values of the immunophenotype features for the diagnostic cases;
 input data processing necessary for the implementaton of the differential diagnostics. The processing includes discretization of the expression values of the markers according to the specified thresholds. The markers with the values greater than the threshold are considered to be expressed and their new value is equal to 1, otherwise the markers are latent and the value is equal to 0. Decision-making module is the main part of the model allowing one to conduct the disease diagnostics on the basis of the available knowledge base and decision inference algorithm.
Knowledge base [3] includes the standard rules and rules developed for all the individual disease subtypes. The developed rules are based on the statistical analysis of the immunophenotype features using the cross-tabulation method.
Decision inference algorithm allows computing the degree of manifestation of the disease subtypes for the input diagnostic case using the model knowledge base.
Output data module provides the following functions:  output data conversion necessary for the formation of the list of disease subtype ordered according to the degree of manifestation.
 output of the list of the disease subtypes with corresponding values of their manifestation.
The models for the diagnostics of leukemia and lymphomas have the identical structure with the differing knowledge base content and different organization of the decision-making module.
The model output list allows estimating the degree of manifestation for each individual disease subtype, where the subtype at the top of the list presents the most probable diagnosis.
III. KNOWLEDGE BASE AND DECISION-MAKING MODULE FOR
THE LEUKOSIS DIAGNOSTICS The general scheme of the decision-making module is presented in Fig. 2 . According to Fig. 2 At the second stage, the specific disease subtype is identified for the determined general group, i. e., the in-depth analysis is pursued. The content of the model knowledge base is presented in Table I .
The set of rules, which includes the number of markers (MPO, CD19, CD3 etc.) according to WHO classification [4] [5] for the biphenotype diagnostics, is the following: The diagnostic rules for the extended groups of leukosis and the corresponding subtypes are presented as the set of weights and importance factors for each marker, which define the profile of the corresponding group or subtype. Weights are received as a result of the statistical analysis of the contingency tables [6] - [7] , constructed for the two nonmetric features. In our case, the two features are immunophenotype feature and disease group or subtype. The example of the weights for the extended leukemia groups is presented in Table II . The weight values indicate the influence of the marker for the diagnostics of the particular leukemia group. Fig. 3 . According to Fig. 3 , the diagnostics is performed separately for children and adults, where for each group the different set of lymphoma subtypes is considered.
The set of diagnostic rules, which comprise the model knowledge base, is presented in Table III .
The same as for leukosis, the diagnostic rules are the set of weights and importance factors for each particular marker, which define the profile of the corresponding lymphoma subtype. 
Identification of the lymphoma subtype for adults Subtypes: chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), hairy cell leukemia (HCL), Non-Hodgkin lymphoma (NHL).
The example of the weights for the adult lymphomas is presented in Table IV . The diagnostic decision is made using the specially developed algorithm. The model knowledge base composed of the set of rules and the binary (discretized marker values) profile of the diagnostic cases is used as the inputs to the algorithm. According to the algorithm, each disease subtype is assigned the value of the degree of manifestation PF. The degree value reflects the correspondence between the disease subtype profile and the marker profile of the patient
. To calculate the PF, the following expression is used:
where PF is the degree value for the particular disease subtype, n C stands for coefficients of the individual markers for the particular disease subtype ( 0 1
, N is the number of the markers with the nonempty values. The coefficients n C are calculated using the marker weights ij  and importance factors ij k as follows:
where i n C stands for marker coefficients for the ith disease subtype, ij  is weight of the jth marker for the ith disease subtype, ij k is importance values for the jth marker for the ith disease subtype, j x is the discretized value of the jth marker. The importance of the individual specific markers for the diagnostic of the particular disease subtype is considered with the importance factor k , e.g., if 2 k  the value of the marker coefficient n C is doubled. For the differential diagnostics, all the values of the immunphenotype features, which characterize the patient, are considered. The decision is also made when not all the marker values are present. However, in the absence of the information for the most specific markers the diagnostics will be inaccurate. 
The example of the decision-making process for the B-ALL diagnostic case with the input values in Table V is considered. The first stage of the leukemia diagnostics is performed, i. e., the recognition of the extended groups: В-ALL, Т-ALL, AML. According to The value of PF consists of two summands: 1 C -the sum of marker coefficients with a positive input value, 2 C -the sum of marker coefficients with a negative input value. 1 C and 2 C are calculated subject to the marker importance factors. For the considered example, C 1 = 6.87 and C 2 = 14.98. to the B-ALL leukemia group. The diagnosis predicted with the model is equal to the true diagnosis.
VI. SOFTWARE FOR THE DIAGNOSTICS OF LEUKEMIA S AND LYMPHOMAS
The proposed models and decision inference algorithm are implemented as software in Visual Studio environment [11] . The software interface for the data input and editing is created dynamically on the basis of the internal electronic presentation of the patient registration card. The process of the decisionmaking is performed using the electronic diagnostic rules, which are stored in the XML files [12] . The main functions, which are implemented, are the following:
 registration and storage of the results of the immune marker analysis on the basis of the XML template of the patient registration card;
 storage of the diagnostic rules for the leukemia and lymphoma subtypes on the basis of the XML templates;
 editing and checking the filling completeness of the patient registration card;
 performing the disease diagnostics according to the developed decision-making models for leukemia and lymphomas;
 adjustment of the disease diagnostics level: leukemia or lymphoma subtypes;
 delivery of the diagnostic results as an ordered list of the disease subtypes with the corresponding degrees of manifestation;
 delivery of the information according to the selected diagnosis and the list of the corresponding coexpressions;  observing and storing the patient registration card;  getting the reference information for the leukemia and lymphoma subtypes. Figure 4 presents the screenshot with the initial patient data and opened control tab -B-ALL marker type.
Software allows making the adjustment of the diagnostic level to select the disease type for further decision-making process (Fig. 5) . After the selection of the certain disease type, the corresponding diagnostic rules are loaded into the computer program. The results of the two-stage leukemia diagnostics are depicted in Fig. 6 , where the initial patient data with known diagnosis Common B-ALL are used. The constituent part of the software system is the electronic help on the basic types of leukemia and lymphoma. The help system allows dynamically browsing the information for each individual leukemia or lymphoma subtype
VII. VERIFICATION OF THE DECISION SUPPORT MODELS
Verification of the decision support model for the diagnostics of the lymphoma subtypes in children was performed using the input dataset with 79 patients, characterized by the expression values of the 31 markers. The same dataset was used for the identification of the individual marker weights for the disease subtypes, i.e., disease subtype profiles, which are used as the diagnostic rules for the disease prediction.
Diagnostic (classification) accuracy for the dataset was equal to 97.5%. Only one data case with Burkitt's lymphoma and one data case with В-cell lymphomas were incorrectly predicted. The classification results are presented in Table VII .
The classification accuracy with the standard combination of markers was equal to 96%. Verification of the decision support model for the diagnostics of the lymphoma subtypes in children was performed using the input dataset with 180 patients, characterized by the expression values of the 13 markers. Diagnostic accuracy for the dataset was equal to 97.2%. Only two data cases with NHL and 3 cases with CLL were incorrectly classified. The classification results are presented in Table VIII .
The classification accuracy with the standard combination of markers was equal to 94%. Verification of the decision support model for the diagnostics of the leukemia subtypes was performed using the input dataset with 577 patients, characterized by the expression values of the 27 markers. At the first stage of diagnostics, 7 data cases were revealed as biphenotypes, among them 3 cases were attributed to B-ALL+T-ALL biphenotype and 4 cases to B-ALL+AML biphenotype. The description of the binary marker profiles of the detected cases with biphenotypes are depicted in Table IX . For these cases the markers, which are specific to several types of leukemia, are simultaneously expressed (e.g., for the first case the T-ALL markers -CD2, CD3, CD5, CD7 and B-ALL markers -CD19, CD20, CD22, CD79). At the first stage of diagnostics, the diagnostic accuracy was 98.8%. Four AML cases and 3 T-ALL cases were incorrectly classified. The classification results are presented in Table X . The classification accuracy with the standard combination of markers was equal to 98.2%. At the second stage of diagnostics, the diagnostic accuracy was 88.3 % for B-ALL subtypes, 82.6 % for T-ALL subtypes. The most number of errors was due to the classification of the AML subtypes (classification accuracy ~70%). Such a result can be explained by the great number of common antigens, expressed on the cell surface of the myeloid and monocytic lines; therefore, the final diagnosis must take into account the results of morphological and cytochemical analysis.
VIII. CONCLUSION
We have developed and implemented as software the decision support models for the immunophenotypical diagnostics of leukosis and lymphomas. These models allow performing the diagnostics using both the standard marker combinations and the diagnostic rules constructed as a result of the analysis of the real dataset stored at the State Institution "Belarusian Research Center for Pediatric Oncology, Hematology and Immunology".
According to the verification on the real datasets of patients with leukemia and lymphomas, the use of the generated diagnostic rules gives slightly better classification accuracy in comparison with the standard combinations.
The software is assigned to support the decision-making for the differential diagnostics of leukemia and lymphomas on the basis of immune marker analysis. The system provides the possibility to register, edit and store the patient data in the XML-format.
Applying the software will allow for more accurate disease diagnostics on the basis of the personalization of the diagnostic process, refining the diagnostics using the specialized decision support models adjusted for marker coexpressions. The software can also be considered an educational tool for training the specialists of the clinicaldiagnostic medical units in order to raise their professional level.
divpakāpju leikožu diagnostikas un limfomu diagnostikas veikšanu, izmantojot izstrādāto diagnostisko likumu kopu, kā arī diagnostikas rezultātu un atbilstošās uzziņu informācijas atainošanu. Ieejas dati ir organizēti atbilstoši vienotajai pacienta reģistrācijas kartei, kas nodrošina darbu dažādos diagnostikas līmeņos: izvērstajā leikožu diagnostikas līmenī, padziļinātajā leikožu diagnostikas līmenī un bērnu un pieaugušo limfomu diagnostikas līmenī. Izstrādātās sistēmas izmantošana veicinās precizētas slimības kartes iegūšanu, ņemot vērā pacienta individuālos ģenētiskos datus, kā arī uzlabos diagnostiku, izmantojot specializētus lēmumu pieņemšanas modeļus leikožu un limfomu imunoloģiski fenotipiskajai diagnostikai, ņemot vērā paralēlo ekspresiju. Tāpat sistēmu var izmantot par mācību līdzekli studenti, zinātnisko grādu pretendenti un praktizējošie speciālisti, apgūstot leikožu un limfomu diagnostikas pamatmetodes, kas izmanto imunoloģiski fenotipiskos rādītājus.
Наталья Новоселова, Игорь Том, Михаель Белевцев. Модели принятия решений и программное обеспечение для дифференциальной иммунофенотипической диагностики лейкозов и лимфом В статье рассматриваются модели принятия решений и соответствующее программное обеспечение, позволяющее помочь специалисту при диагностике лейкозов и лимфом по результатам иммунофенотипирования. Базы знаний моделей включают в себя наборы правил по диагностике лейкозов и лимфом, которые построены на основе статистического анализа базы диагностических случаев, накопленной в государственном учреждении «Республиканский научно-практический центр детской онкологии, гематологии и иммунологии», а также стандартные правила. Правила для диагностики основных групп лейкозов, лимфом и соответствующих им подтипов заболевания представляют собой наборы весовых коэффициентов и коэффициентов важности для каждого диагностического маркера, которые определяют профиль соответствующей группы или подтипа. Весовые коэффициенты были получены на основе статистического анализа таблиц сопряженности. Диагностическое решение выносится с использованием специально разработанного алгоритма, позволяющего рассчитать степени выраженности подтипов заболевания на основе входных значений иммунофенотипических показателей с использованием базы знаний модели. Диагностические модели для лейкозов и лимфом имеют общую модульную структуру с отличающимся составом диагностических правил и организацией модуля принятия решений. Выходные данные модели представляются в виде упорядоченного списка подтипов заболевания, что позволяет оценить степень выраженности каждого из подтипов заболевания для конкретного диагностического случая. Вверху списка располагается наиболее вероятный подтип. Специализированное программное обеспечение реализует разработанные модели принятия решений, обеспечивая проведение двухуровневой диагностики лейкозов и диагностику лимфом с использованием набора разработанных диагностических правил, просмотр результатов диагностики и соответствующей справочной информации. Входные данные организованы согласно унифицированной регистрационной карте пациента, обеспечивающей возможность работы на разных уровнях диагностики: уровень расширенной диагностики лейкозов, уровень углубленной диагностики лейкозов, уровень диагностики лимфом для детей и взрослых. Использование разработанной системы будет способствовать получению уточненной картины заболевания с учетом индивидуальных генетических данных пациента, совершенствованию диагностики за счет использования специализированных моделей принятия решений для иммунофенотипической диагностики лейкозов и лимфом с учетом коэкспрессий. Система также может быть использована в качестве обучающего средства для студентов, аспирантов, практикующих специалистов по основным методам диагностики лейкозов и лимфом по набору иммунофенотипических показателей.
